It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home> Pubblicazioni

Studi di fase III

Dati di HAWK & HARRIER - Settimana 96

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, et al. HAWK and HARRIER: 96-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-related Macular Degeneration. Ophthalmology 2020; in fase di pubblicazione.

Dati di HAWK & HARRIER - Settimana 48

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2020;127:72–84.

Studi di fase II

Studio OSPREY

Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 2017;124:1296–304.

Studio SEE

Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology 2016;123:1080–9.

Relazioni dell'SRC (Safety Review Commitee)

Relazione preliminare

Safety Review Committee. Novartis-Appointed Safety Review Committee Reports Initial Brolucizumab Findings. Pubblicata a giugno 2020

Revisione post-hoc degli studi HAWK e HARRIER

Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, et al. Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER. Ophthalmology 2020; in press